Kamada Ltd. (KMDA)
NASDAQ: KMDA
· Real-Time Price · USD
6.53
0.06 (0.93%)
At close: May 01, 2025, 3:59 PM
6.57
0.61%
After-hours: May 01, 2025, 04:05 PM EDT
0.93% (1D)
| Bid | 6.18 |
| Market Cap | 375.51M |
| Revenue (ttm) | 160.02M |
| Net Income (ttm) | 14.46M |
| EPS (ttm) | 0.25 |
| PE Ratio (ttm) | 26.12 |
| Forward PE | 17.2 |
| Analyst | Buy |
| Ask | 6.75 |
| Volume | 28,597 |
| Avg. Volume (20D) | 205,926 |
| Open | 6.58 |
| Previous Close | 6.47 |
| Day's Range | 6.52 - 6.65 |
| 52-Week Range | 4.74 - 9.15 |
| Beta | 0.28 |
About KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurre...
Sector Healthcare
IPO Date May 31, 2013
Employees 420
Stock Exchange NASDAQ
Ticker Symbol KMDA
Website https://www.kamada.com
Analyst Forecast
According to 3 analyst ratings, the average rating for KMDA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 129.71% from the latest price.
Stock ForecastsNext Earnings Release
Kamada Ltd. is scheduled to release its earnings on May 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+7.41%
Kamada shares are trading higher after the company...
Unlock content with
Pro Subscription
3 months ago
+6.36%
Kamada shares are trading higher after the company announced a contract award for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027.
